Vaishali Sanchorawala MD
Professor, Hematology & Medical Oncology
Associate Director, Amyloidosis Center
72 E. Concord Street | (617) 358-4750vaishali.sanchorawala@bmc.org
vsanchor@bu.edu

Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Biography
72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Other Positions
Education
MBBS, Seth G.S. Medical College
Publications
Anand S, O'Neill-Dee M, Sanchorawala V, Verma A. Light-chain (AL) amyloidosis for nephrologists-treatment standard. Nephrol Dial Transplant. 2024 Dec 20; 40(1):34-47. PMID: 39375844.
Published on 12/19/2024Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, Kumar S, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Schönland SO, Lentzsch S, Muchtar E. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood. 2024 Dec 19; 144(25):2613-2624. PMID: 39197073.
Published on 12/10/2024Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.
Published on 12/6/2024Morgan GJ, Nau AN, Wong S, Spencer BH, Shen Y, Hua A, Bullard MJ, Sanchorawala V, Prokaeva T. An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis. Amyloid. 2024 Dec 06; 1-10. PMID: 39641756.
Published on 12/3/2024Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2024 Dec 03. PMID: 39624016.
Published on 11/26/2024Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.
Published on 11/16/2024Morgan GJ, Yung Z, Spencer BH, Sanchorawala V, Prokaeva T. Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis. Pharmaceuticals (Basel). 2024 Nov 16; 17(11). PMID: 39598451.
Published on 11/4/2024Dodge MC, Prokaeva T, Mendelson L, Joshi T, Sanchorawala V, Kataria Y. High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis. J Appl Lab Med. 2024 Nov 04. PMID: 39495058.
Published on 10/1/2024Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. JAMA Oncol. 2024 Oct 01; 10(10):1362-1369. PMID: 39088206.
Published on 9/26/2024Sanchorawala V. Systemic Light Chain Amyloidosis. Reply. N Engl J Med. 2024 Sep 26; 391(12):1165-1166. PMID: 39321377.
Media Mentions
Published on 10/13/2024
New study underway in Boston for people with advanced stage of AL amyloidosis
Published on 6/27/2024
: Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/27/2024
Early diagnosis key in combating the deadly effects of AL amyloidosis
Published on 6/26/2024
Published on 6/26/2024
Published on 9/22/2022
There’s New Proof Crispr Can Edit Genes Inside Human Bodies
Published on 8/5/2022
Young Black Patients With AML Face Significantly Worse Outcomes
Published on 7/20/2022
Stem Cell Transplantation Shows Promise in AL Amyloidosis
Published on 7/14/2022
Published on 7/14/2022
View full list of 15 media mentions.